
Artivion (AORT) Stock Forecast & Price Target
Artivion (AORT) Analyst Ratings
Bulls say
Artivion is a leading medical device company that provides a suite of aortic-centric solutions to cardiac and vascular surgeons. The company has two reportable segments: Medical Devices and Preservation Services. Its strong Q4 performance, including a 18.5% year-over-year revenue growth and a 29% increase in adjusted EBITDA, is a testament to its continued success and potential for growth. With a diverse product portfolio and a strong presence in North America and other global markets, Artivion is well-positioned to capitalize on the growing demand for aortic treatments worldwide.
Bears say
Artivion is expected to experience strong revenue growth and margin improvement due to its promising product portfolio, pipeline, and international expansion efforts. The company's 12-month price target of $58 is based on an EV/sales multiple of 6.0x its 2026 estimated sales, which is higher than its peers in the medical device and cardiovascular industries. Potential upside drivers include new product launches and approvals, as well as stronger than expected margin improvement and EBITDA growth.
This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares